ClinicalTrials.gg

Program

Androgen Receptor Antagonist TQB3720

In Sino Biopharmaceutical’s pipeline, 雄激素受体 (AR) 拮抗剂. Its studies are mostly in Prostatic Neoplasms, led by Sino Biopharmaceutical.

Furthest: phase 1, since Apr 20, 20211 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical10 open or runningphase 1since Apr 20, 2021Apr 20, 2021none ahead
  • Named in Sino Biopharmaceutical’s own pipeline as TQB3720, phase 1, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 20, 2021First study: phase 1 study in Metastatic Castration-resistant Prostate CancerFirst studyNCT04853498 · 192 enrolled · China

TargetBeta

“雄激素受体 (AR) 拮抗剂”the company's pipeline, read by Claude · source

Other programs on AR

ProgramCompanyFurthest phaseStudies
enzalutamideruleAstellas Pharmaphase 469
apalutamideruleJohnson & Johnsonphase 431
darolutamideruleBayerphase 426
Clascoteronerulecassiopea-spaphase 419
ostarinerulegtxphase 315
rezvilutamideruleJiangsu HengRui Medicinephase 313
dezandrodegruleBristol-Myers Squibbphase 35
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915Johnson & Johnsonphase 33
HRS-5041Jiangsu HengRui Medicinephase 26
luxdegalutamideNovartisphase 23
luxdegalutamideNovartisphase 22

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04853498Metastatic Castration-resistant Prostate Cancer · China1TerminatedApr 30, 2024192

How it is read

Names in the registry

  • “TQB3720”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.